Research Article
The Preoperative Assessment of Hepatic Tumours: Evaluation of UK Regional Multidisciplinary Team Performance
Table 1
MDT indications for resection and number with discrepant histological diagnoses.
| | Primary MDT diagnosis | Number (%) | Median age (range) | Male/female | Discrepant diagnosis (%) |
| | Colorectal liver metastases (CRM) | 279 | (64) | 67 | (33–90) | 176/103 | 10 | (3.6) | | Hepatoma | 44 | (10) | 63 | (33–84) | 31/13 | 13 | (30) | | Hilar cholangiocarcinoma | 28 | (7) | 67 | (32–77) | 14/14 | 7 | (25) | | Other metastases | 24 | (5) | 62 | (32–76) | 8/16 | 1 | (4) | | Gall bladder carcinoma | 20 | (5) | 61 | (41–82) | 5/15 | 1 | (5) | | Neuroendocrine tumour (NET) | 11 | (3) | 51 | (41–77) | 8/3 | 0 | — | | Metastasis of unknown origin | 6 | (1) | 63 | (43–73) | 4/2 | 5 | (83) | | Biliary cystadenoma | 6 | (1) | 34 | (21–43) | 0/6 | 0 | — | | Focal nodular hyperplasia (FNH) | 5 | (1) | 34 | (30–38) | 0/5 | 0 | — | | Hepatocellular adenoma | 4 | (<1) | 31 | (30–39) | 0/4 | 0 | — | | Benign cyst | 3 | (<1) | 52 | (47–65) | 0/3 | 1 | (33) | | Breast metastases | 3 | (<1) | 67 | (45–78) | 0/3 | 3 | (100) | | Peripheral cholangiocarcinoma | 3 | (<1) | 70 | — | 2/1 | 1 | (33) | | Primary sarcoma | 1 | (<1) | 71 | — | 0/1 | 0 | — | | Haemangioma | 1 | (<1) | 33 | — | 0/1 | 0 | — |
| | Total | 438 | | 65 | (21–90) | 248/190 | 42 | (9.8) |
|
|
